BioSpace News Archive

Alcami Corporation, a leading contract development and manufacturing organization, announced the retirement of Patrick Walsh and the subsequent appointment of Bill Humphries as the next CEO, effective June 5th, 2023.

Tiziana Life Sciences Ltd. announced a reduction in microglial activation as seen in 3-month Positron Emission Tomography scans that has now been seen in a total of 5 of the 6 patients with non-active secondary-progressive multiple sclerosis treated with intranasal foralumab in its Expanded Access program.

Innovation Pharmaceuticals is pleased to inform shareholders that BeaMed, a pioneering company dedicated to revolutionizing epilepsy and cancer surgery through laser-based innovations, reported significant progress in the development of its groundbreaking StingRay Laser system.

IASO Biotechnology and Innovent Biologics, Inc., jointly announced the updated data from phase 1b/2 study of Equecabtagene Autoleucel, a fully-human anti-B cell maturation antigen chimeric antigen receptor T-cell therapy for the treatment of relapsed and/or refractory multiple myeloma, was presented at the American Society of Clinical Oncology Annual Meeting in Chicago on June 2-6, 2023.

Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, announces the first presentation of its DF1001 TriNKET immune engager clinical data at the ASCO 2023 Annual Meeting in Chicago.

The Society of Obstetricians and Gynaecologists of Canada will be holding its Annual Clinical and Scientific Conference this June 6-9 in Ottawa.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that results from the Phase 3 CARTITUDE-4 study showed CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) reduced the risk of disease progression or death by 74 percent compared to two standard of care treatment (SOC) regimens, pomalidomide, bortezomib and dexamethasone (PVd) or daratumumab, pomalidomide and dexamethasone (DPd).

Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the “Company” or “Telo”) is excited to announce that the results of its smoldering multiple myeloma (SMM) studies that were conducted in collaboration with the Mayo Clinic were presented earlier today at the American Society of Clinical Oncology (ASCO) 2023 annual meeting.

Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQB: KHRNF) (“Khiron” or the “Company”) announced today that the Company has agreed to a $500,000 non-interesting bearing refundable deposit from 2518542 Alberta Ltd. (“251"), a company controlled by Avonlea-Drewry Holdings Inc.

Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, will be presenting at the 13th Annual LD Micro Invitational being held at the Luxe Sunset Boulevard Hotel, California June 6th-8th, 2023. The Company will also be available for 1:1 meetings.